AbbVie updated its FY 2025 earnings guidance, providing an EPS range of $11.67 to $11.87 and Q2 2025 EPS guidance of $2.84 to $2.88. The company expects combined Q2 sales of $6 billion from its key immunology drugs, Skyrizi and Rinvoq, which have shown strong performance across all approved indications. This robust sales performance is expected to support AbbVie's return to growth in 2025, despite the recent loss of exclusivity for Humira. The company also continues to expand in oncology and neuroscience, further strengthening its growth outlook.
